Invivyd Expects To End 2024 With At Least $75M In Cash Based On Expected Net Product Revenue Of $150M-$200M
Portfolio Pulse from Benzinga Newsdesk
Invivyd expects to end 2024 with at least $75 million in cash, based on anticipated net product revenue of $150 million to $200 million. The company maintains its guidance, which was based on PEMGARDA being authorized for PrEP of moderate to severe COVID-19 in certain immunocompromised people.
August 14, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Invivyd expects to end 2024 with at least $75 million in cash, based on anticipated net product revenue of $150 million to $200 million. The guidance is based on PEMGARDA's potential authorization for COVID-19 PrEP.
The projected cash position and revenue expectations are positive indicators for Invivyd's financial health. The potential authorization of PEMGARDA for COVID-19 PrEP could further boost revenue, making the stock likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100